Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 13/20 | 0.44 |
| ▸ | JAK3 | P52333 | 11/20 | 0.43 |
| ▸ | JAK2 | O60674 | 10/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.38 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.38 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.38 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14494146 | 1.00 | JAK1 (0.44) | JAK1JAK3JAK2TYK2PIK3CD | |
| SCHEMBL2630353 | 0.88 | JAK3 (0.55) | JAK1JAK3JAK2TYK2GUCY1B2 | |
| SCHEMBL2630352 | 0.88 | JAK3 (0.55) | JAK1JAK3JAK2TYK2GUCY1B2 | |
| SCHEMBL16376342 | 0.85 | GUCY1B2 (0.38) | JAK3JAK2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL16376343 | 0.85 | GUCY1B2 (0.38) | JAK3JAK2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL10125142 | 0.84 | JAK1 (0.44) | JAK1JAK3JAK2TYK2 | |
| SCHEMBL10044624 | 0.82 | GUCY1B2 (0.40) | JAK3JAK2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL10044611 | 0.82 | GUCY1B2 (0.40) | JAK3JAK2GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL5635534 | 0.82 | JAK3 (0.42) | JAK1JAK3JAK2 | |
| SCHEMBL5635543 | 0.82 | JAK3 (0.42) | JAK1JAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-8921376-B2 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-12-30 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | VERTEX PHARMACEUTICALS INCORPORATED | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135466-A1 | Pyrrolopyridines useful as inhibitors of protein kinase | JAK2, JAK1, JAK3 | JAK1 2/4885JAK3 3/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.